Pharmacists’ perspectives on monitoring adherence to treatment in Cystic Fibrosis
- 29 December 2015
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 38 (2) , 296-302
Abstract
Background Cystic Fibrosis (CF) management requires complex treatment regimens but adherence to treatment is poor and has negative health implications. There are various methods of measuring adherence, but little is known regarding the extent of adherence measurement in CF centres throughout the UK and Ireland. Objective To determine the adherence monitoring practices in CF centres throughout the UK and Ireland, and to establish CF pharmacists’ views on these practices. Setting UK and Ireland Cystic Fibrosis Pharmacists’ Group’s annual meeting (2014). Methods A questionnaire was designed, piloted and distributed to pharmacists attending the UK and Ireland Cystic Fibrosis Pharmacists’ Group’s annual meeting (2014). The main outcome measures were the methods of inhaled/nebulised antibiotic supply and the methods used to measure treatment adherence in CF centres. The questionnaire also ascertained the demographic information of participating pharmacists. Closed question responses were analysed using descriptive statistics. Open questions were analysed using content analysis. Results Twenty-one respondents (84 % response) were included in the analysis and were mostly from English centres (66.7 %). Detailed records of patients receiving their inhaled/nebulised antibiotics were lacking. Adherence was most commonly described to be measured at ‘every clinic visit’ (28.6 %) and ‘occasionally’ (28.6 %). Patient self-reported adherence was the most commonly used method of measuring adherence in practice (90.5 %). The availability of electronic adherence monitoring in CF centres did not guarantee its use. Pharmacists attributed an equal professional responsibility for adherence monitoring in CF to Consultants, Nurses and Pharmacists. Seventy-six percent of pharmacists felt that the current adherence monitoring practices within their own unit were inadequate and associated with the absence of sufficient specialist CF pharmacist involvement. Many suggested that greater specialist pharmacist involvement could facilitate improved adherence monitoring. Conclusion Current adherence knowledge is largely based on self-report. Further work is required to establish the most appropriate method of adherence monitoring in CF centres, to improve the recording of adherence and to understand the impact of increased specialist pharmacist involvement on that adherence.Keywords
Funding Information
- Gilead Sciences (US)
This publication has 21 references indexed in Scilit:
- Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trialBritish Journal of Clinical Pharmacology, 2014
- Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosisRespiratory Medicine, 2011
- Longitudinal association between medication adherence and lung health in people with cystic fibrosisJournal of Cystic Fibrosis, 2011
- Adherence monitoring in drug deliveryExpert Opinion on Drug Delivery, 2010
- High treatment burden in adults with cystic fibrosis: Challenges to disease self-managementJournal of Cystic Fibrosis, 2009
- Evidence-based Assessment of Adherence to Medical Treatments in Pediatric PsychologyJournal of Pediatric Psychology, 2007
- A multi-method assessment of treatment adherence for children with cystic fibrosisJournal of Cystic Fibrosis, 2006
- Three Approaches to Qualitative Content AnalysisQualitative Health Research, 2005
- Economic evaluation of Tobramycin nebuliser solution in cystic fibrosisJournal of Cystic Fibrosis, 2003
- Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practiceClinical Therapeutics, 1999